Back to Search
Start Over
Assessing MicroRNA-375 Levels in Type 2 Diabetes Mellitus (T2DM) Patients and Their First-Degree Relatives with T2DM
- Source :
- Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol Volume 14, Pp 1445-1451 (2021)
- Publication Year :
- 2021
- Publisher :
- Informa UK Limited, 2021.
-
Abstract
- Xu Wu, Yashan Li, Baohua Man, Dexuan Li The Third People’s Hospital of Yunnan Province, Department of Clinical Laboratory, Kunming, 650200, People’s Republic of ChinaCorrespondence: Dexuan LiDepartment of Clinical Laboratory, The Third People’s Hospital of Yunnan Province, No. 292 Beijing Road, Kunming, 650200, People’s Republic of ChinaEmail 147347278@qq.comPurpose: The pancreatic islet specific microRNA-375 (miR-375) is overexpressed in type 2 diabetes mellitus (T2DM) patients suppressing the glucose-induced insulin secretion. Thus, miR-375 may serve as a biomarker for the early prediction of T2DM among high-risk individuals. We conducted this clinical study to assess the significance of miR-375 among type 2 diabetes mellitus (T2DM) patients and their first-degree relatives.Patients and Methods: We included 56 Han Chinese individuals (N: NGT = 21, T2DM = 10, FD-NGT =13 and FD-T2DM = 12) who received medical health check-ups from January 2018 to September 2018 at The Third Hospital of Yunnan Province, China. They were categorized as normal glucose tolerance (NGT), T2DM, first-degree relatives with normal glucose tolerance (FD-NGT) and first-degree relatives with T2DM (FD-T2DM). OGTT, C-peptide and Insulin tests were performed to confirm the diagnosis. The miR-375 levels were determined by Quantitative real-time RT-PCR (qRT-PCR).Results: The OGTT test showed a significant difference in T2DM and FD-T2DM groups compared with NGT and FD-NGT (p< 0.05). Similar results were observed during C-peptide and insulin tests. Interestingly, the 2-hour insulin test showed FD-NGT group having a significantly higher mean ± standard error of (64.240 ± 12.775) compared to NGT (28.836 ± 10.875). Assessment of miR-375 expression levels in 4 groups showed a significant up-regulation in T2DM and FD-T2DM compared with NGT and FD-NGT groups. A slight increase in miRNA expression was observed in FD-NGT compared with NGT group but was not statistically significant.Conclusion: The OGTT, C-peptide and insulin tests revealed a statistically significant difference in T2DM and FD-T2DM compared with NGT and FD-NGT groups. A significantly higher miR-375 expression was also observed in T2DM and FD-T2DM groups compared with NGT and FD-NGT and thus, miR-375 may serve as a stable biomarker for the early prediction of T2DM among high-risk individuals.Keywords: C-peptide, insulin, microRNA-375, OGTT, type 2 diabetes mellitus
- Subjects :
- insulin
endocrine system
medicine.medical_specialty
endocrine system diseases
type 2 diabetes mellitus
medicine.medical_treatment
microRNA-375
Specialties of internal medicine
030209 endocrinology & metabolism
030204 cardiovascular system & hematology
Gastroenterology
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Internal medicine
microRNA
OGTT
Internal Medicine
medicine
First-degree relatives
Targets and Therapy [Diabetes, Metabolic Syndrome and Obesity]
Original Research
Pharmacology
geography
geography.geographical_feature_category
business.industry
C-peptide
Insulin
nutritional and metabolic diseases
Type 2 Diabetes Mellitus
Islet
Standard error
RC581-951
chemistry
Biomarker (medicine)
business
hormones, hormone substitutes, and hormone antagonists
Subjects
Details
- ISSN :
- 11787007
- Volume :
- 14
- Database :
- OpenAIRE
- Journal :
- Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
- Accession number :
- edsair.doi.dedup.....368a4d683dd89153681be82db69dee12
- Full Text :
- https://doi.org/10.2147/dmso.s298735